Amivas (US) LLC picked up seven years of orphan drug exclusivity with the US Food and Drug Administration’s nod for its malaria drug artesunate, but whether the company also will pocket a tropical disease priority review voucher remains to be seen.
On 26 May, the agency approved Amivas’ artesunate for injection for initial treatment of severe malaria in adult and pediatric...






